Kontafarma China Holdings Ltd Fundamental Analysis
Kontafarma China Holdings Ltd (1312.HK) shows weak financial fundamentals with a PE ratio of -0.38, profit margin of -46.77%, and ROE of -69.10%. The company generates $0.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -104.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1312.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1312.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1312.HK trades at attractive valuation levels.
Growth Score
Weak1312.HK faces weak or negative growth trends.
Financial Health Score
Moderate1312.HK shows balanced financial health with some risks.
Profitability Score
Weak1312.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1312.HK Expensive or Cheap?
P/E Ratio
1312.HK trades at -0.38 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1312.HK's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Kontafarma China Holdings Ltd at 0.29 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -1.69 times EBITDA. This is generally considered low.
How Well Does 1312.HK Make Money?
Net Profit Margin
For every $100 in sales, Kontafarma China Holdings Ltd keeps $-46.77 as profit after all expenses.
Operating Margin
Core operations generate -22.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-69.10 in profit for every $100 of shareholder equity.
ROA
Kontafarma China Holdings Ltd generates $-40.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kontafarma China Holdings Ltd generates limited operating cash flow of $71.11M, signaling weaker underlying cash strength.
Free Cash Flow
Kontafarma China Holdings Ltd produces free cash flow of $47.59M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.01 in free cash annually.
FCF Yield
1312.HK converts 29.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.38
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.18
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.37
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.79
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.69
vs 25 benchmark
ROA
Return on assets percentage
-0.40
vs 25 benchmark
ROCE
Return on capital employed
-0.34
vs 25 benchmark
How 1312.HK Stacks Against Its Sector Peers
| Metric | 1312.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.38 | 31.13 | Better (Cheaper) |
| ROE | -69.10% | 1156.00% | Weak |
| Net Margin | -46.77% | -1203.00% (disorted) | Weak |
| Debt/Equity | 0.37 | 0.61 | Strong (Low Leverage) |
| Current Ratio | 0.79 | 3.45 | Weak Liquidity |
| ROA | -40.17% | 556.00% | Weak |
1312.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kontafarma China Holdings Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Commodity, Value
EPS CAGR
N/A
Industry Style: Cyclical, Commodity, Value
FCF CAGR
N/A
Industry Style: Cyclical, Commodity, Value